AITech.euabout 1 hour ago
ALP Bio raises €161K for biologic safety
2 min read
Swiss startup ALP Bio secured 150,000 Swiss francs from Venture Kick to advance a platform combining human tonsil-derived immune models with artificial intelligence. The technology predicts how the immune system responds to therapeutic antibodies before clinical trials begin. This funding supports pilot projects that validate immunogenicity risks early in drug development for next-generation biologic medicines.
Level
Hype check
Tap to vote and see what everyone thinks.
